Arcus Biosciences (RCUS) Common Equity (2017 - 2026)

Arcus Biosciences' Common Equity history runs 10 years deep, the most recent figure standing at $524.0 million for Q1 2026.

• On a quarterly basis, Common Equity fell 1.32% year-over-year to $524.0 million in Q1 2026; TTM through Mar 2026 was $524.0 million, a 1.32% decrease from a year earlier, with the FY2025 full-year figure at $631.0 million, up 30.1% from the prior year.
• Common Equity declined to $524.0 million in Q1 2026 per RCUS's latest filing, from $631.0 million in the prior quarter.
• Across five years, Common Equity topped out at $797.0 million in Q1 2022 and bottomed at $436.0 million in Q3 2025.
• The 5-year median for Common Equity is $566.0 million (2023), against an average of $594.8 million.
• Across the five-year window, Common Equity slipped 29.68% in 2023 and soared 30.1% in 2025, its largest moves.
• Year by year, Common Equity stood at $657.0 million in 2022, then fell by 29.68% to $462.0 million in 2023, then grew by 4.98% to $485.0 million in 2024, then soared by 30.1% to $631.0 million in 2025, then retreated by 16.96% to $524.0 million in 2026.
• Per Business Quant, the three latest RCUS Common Equity figures stand at $524.0 million (Q1 2026), $631.0 million (Q4 2025), and $436.0 million (Q3 2025).